Kornimate/medical-research-clean huggingface dataset:
assessment of the accuracy of full digital workflow in patient specific submerged subperiosteal implants: a case series study

Conditions: Edentulous Alveolar Ridge Atrophy; ATROPHYC EDENTULOUS JAW; Edentulous Maxilla; Edentulous Alveolar Ridge In Mandible

Summary: custom made subperiosteal implants will be designed using the patients' ct data and will be inserted with the help of a surgical guide and loaded by a screw retained full arch prosthesis. accuracy will be assessed


Eligibility criteria:
inclusion criteria: * adults patients with severely atrophic alveolar ridges in both maxilla and mandible. exclusion criteria: * alveolar bone dimensions that can allow for root form implant placement
a study to investigate the efficacy and safety of rilzabrutinib in adult participants with graves' disease

Conditions: Graves' Disease

Summary: this is a parallel group, phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with graves' disease, with and without graves' orbitopathy, aged 18 years or older. study details include: * screening period (up to 4 weeks). * treatment period (up to 16 weeks). * follow-up period (4 weeks). the number of visits will be up to 13.


Eligibility criteria:
inclusion criteria: * participants who have a confirmed diagnosis of graves' disease with active hyperthyroidism, with or without active graves' orbitopathy at the time of screening. * a subset of participants will have a diagnosis of active graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (cas) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and/or intermittent or constant diplopia. * contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. exclusion criteria: * history of hyperthyroidism not caused by graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis). * history of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician. * enlarged thyroid goiter causing upper airway obstruction and/or requiring surgical intervention during the study period. * for participant with graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery/irradiation during the course of the study. * sight threatening graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months. * corneal decompensation unresponsive to medical management. * onset of graves' orbitopathy symptoms \>9 months prior to baseline. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
the effect of the walking exercise training given according to transtheoretical model, and follow-up on improving exercise behavior and metabolic control in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: objective this study aims to find out the effects of walking exercise training, which is given according to transtheoretical model (ttm), and follow-up on improving exercise behavior and metabolic control in type 2 diabetic patients. research design and methods the study was conducted as a pre-test, post-test experimental model with 76 intervention (int) groups and 76 control (con) groups adult type 2 diabetic patients providing the criteria of the study and followed-up by the diabetes polyclinic of adıyaman education and research hospital. patient introduction form (pif), ttm scales and pedometer were used to collect the data. ttm based training was given to the intervention group according to the patients' change stages at hospital 10 weeks once per every 2 weeks. pif, ttm scales were applied after the training. pif, ttm scales were applied to the groups 9 months after the pre-test again.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with type-2 diabetes at least six months before, received basic diabetes information, received insulin and/or oral antidiabetic treatment, whose arterial blood pressure was in systolic ≤ 160 mmhg and diastolic ≤ 100 mmhg, who had hba1c 7% and over, who were literate and had no communication problems were included in the study. exclusion criteria: * those who had developed diabetes-related complications (advanced), were pregnant, diagnosed with cancer, had physical and mental problems that prevent walking were excluded from the study.

Keywords: type 2 diabetes mellitus metabolic control walking exercise transtheoretical model nurse
cardiac effects of rotigotine transdermal system in subjects with advanced-stage idiopathic parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. moxifloxacin infusion is used as positive control to assess assay sensitivity.


Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age * advanced-stage idiopathic parkinson's disease requiring treatment with levodopa. * nonchildbearing potential exclusion criteria: * atypical parkinson's syndrome(s). * history of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant. * significant tremor or dyskinesias. * severe dysfunction of the autonomic nervous system. * history of transient ischemic attack or stroke within the last 12 months. * conduction abnormality or relevant cardiac dysfunction and/or myocardial infarction within last 12 months. * history or current condition of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia), or a family history of long qt syndrome and/or of torsade de pointes. * no stable sinus rhythm: more than 20 ectopics/h. * any other clinically relevant ecg abnormality. * history or current condition of epilepsy and/or seizures. * history or current condition of atopic or eczematous dermatitis, psoriasis, or another active skin disease. * history or current condition of symptomatic orthostatic hypotension. * history or current condition of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis. * history of glucose 6-phosphate dehydrogenase deficiency. * history of tendonitis or tendon rupture with quinolone antibiotics. * renal or hepatic dysfunction. * treatment with dopamine agonists, mao a inhibitors, reserpine, or alpha-methyldopa * therapy known to produce a nontrivial prolongation of the qt interval.

Keywords: advanced-stage idiopathic parkinson's disease
evaluation of non-cultured epidermal cellular grafting vs hyaluronic acid for repigmenting vitiligo and piebaldism

Conditions: Vitiligo; Piebaldism

Summary: the purpose of this study is to assess the efficacy of autologous epidermal cells suspension grafting using a newly developed device named viticell® compared to placebo. the secondary objective is to evaluate safety of viticell® and global satisfaction of patient and investigator.


Eligibility criteria:
inclusion criteria: * men and women aged over 18 years old with a diagnosis of non-scaring leukoderma that has been stable over the last 2 years (non-segmental, segmental vitiligo and piebaldism) * for non-segmental vitiligo: symmetrical vitiligo lesions, or parts of a lesion. a part of at least 1 cm2 (1 x 1 cm), but preferable 4 cm2 (2x2 cm) and preferably in the center of each lesions (left/right) should be treated. the minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm. * for segmental vitiligo lesion and piebaldism: all lesions possible if two parts of at least 1 cm2 (1 x 1 cm), but preferably 4 cm2 (2 x 2 cm) in the lesion can be treated. the minimum distance between the 2 areas should be 2 cm and between test areas and to the normal pigmented skin preferably at least 0.5 cm. * medical treatments of vitiligo failed (in case of vitiligo: at least cream treatment for 6 months). * absence of infected lesion * negative serology (hiv-hepatitis b and c- syphilis) * without treatment one month for cream and 3 months for phototherapy exclusion criteria: * hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid) * indication against biopsies * patient with a history of melanoma * positive serology (ongoing serious systemic disease, herpes, hiv, hepatitis b and c-syphilis) * positive pregnancy test * history of keloidal scars and presence of koebner's phenomenon (type 1 and type 2b) * infected lesion * test areas not on fingers and toes vitiligo areas in case of non-segmental vitiligo * test areas not on facial non segmental vitiligo * pregnant women, or lactating * age \<18years * major deprived of their freedom by administrative or legal decision, or being the subject of a legal protection measure, or out of state to express their consent
reducing hypotensive anesthesia use with txa during orthognathic surgery

Conditions: Hypotension During Surgery; Blood Loss, Surgical

Summary: this prospective study will analyze the need for deliberate hypotensive anesthesia (dha) during orthognathic surgery when tranexamic acid (txa) is administered. dha has been proven to be effective although it comes with multiple risks related to organ hypoperfusion including kidney injury, stroke, and cardiac ischemia. therefore, it may be potentially safer for patients to avoid deliberate hypotensive anesthesia if txa alone adequately controls blood loss and provides adequate surgical site visualization.

our goal is to enroll 50 patients. patients will be recruited from dr. kinard's regularly scheduled orthognathic cases at uab highlands hospital. the patient will be informed of the study in advance and have consent signed pre-operatively. patients will be evaluated for the following variables: sex, age, weight at time of surgery, preoperative hemoglobin, and preoperative hematocrit. patients will be included if they are undergoing bimaxillary orthognathic surgery at uab highlands hospital. all patients treated with orthognathic surgery already are provided 1g of txa perioperatively and this will be continued through this study. all patients will be treated with 1g of txa perioperatively and the anesthesia team will be instructed to limit deliberate hypotensive anesthesia unless otherwise directed by the surgeon. perioperative and post-operative measurements will include: estimated blood loss, pre and post-operative hemoglobin, pre and post-operative hematocrit, average mean arterial pressure throughout the case (map), maximum map (excluding induction and emergence), minimum map (excluding induction and emergence), total map time under 65 mmhg, length of procedure, and surgeon evaluation of visual field throughout the procedure utilizing fromme's ordinal scale. based on these factors, it will help determine the need for deliberate hypotensive anesthesia during orthognathic surgery when tranexamic acid is administered.

Eligibility criteria:
inclusion criteria: * bimaxillary orthognathic surgery completed at uab highlands hospital exclusion criteria: * history of hypertension or previously diagnosed cardiac problems * bleeding diathesis * txa medically contraindicated

Keywords: orthognathic surgery
early prediction and randomised prevention of preeclampsia with low dose aspirin in chinese cohort

Conditions: Preeclampsia

Summary: this study intends to adopt the method of multi-center prospective randomized controlled study. the aim of this study is to obtain localized excision values through a preeclampsia screening model established in early pregnancy, and to evaluate the efficacy of low-dose aspirin intervention for preeclampsia prevention in pregnant women at high risk of screening.


Eligibility criteria:
inclusion criteria: * 1)pregnant women assessed as at high risk of preeclampsia 2) live pregnancy 3) gestational weeks \< 16 weeks 4) agree to randomized drug intervention studies 5) follow up regularly and obtain reliable pregnancy outcomes exclusion criteria: * 1)with severe fetal or chromosomal abnormalities 2) induced labor or spontaneous abortion due to social factors 3) absolute or relative contraindications to aspirin use (allergy to aspirin or other salicylate, or other ingredients of the drug;acute gastrointestinal ulcer;active bleeding;in patients with severe g6pd deficiency, acetylsalicylic acid may induce hemolysis or hemolytic anemia.aspirin asthma)

Keywords: preeclampsia aspirin prediction intervention papp-a pigf sflt
the pops-titration versus the slow-coagulation cyclophotocoagulation in treatment of refractory glaucoma

Conditions: Glaucoma; Intraocular Pressure

Summary: * transcleral cyclophotocoagulation (tscpc) has long been used as refractory glaucoma management and is very easy to learn and easy to perform. * recent advances in laser technology; the role of tscpc is being expanded because it has benefits of noninvasive glaucoma procedure. * the titration (pops), the fixed high-energy, and the fixed-low energy (slow-coagulation) are three energy delivery techniques. * the present study would report on the outcome (efficacy and safety) of the slow-coagulation versus the titration method in treatment of refractory glaucoma with dark iris. * the results would provide reliable evidences to supplement clinical judgment when making a decision in favor of each treatment method for glaucoma patients.

* several protocols afford delivery of the "optimum" dose of laser energy per session necessary to achieve a long-term effective ocular hypotensive response balancing risks related to a high energy treatment and risks related to retreatment due to suboptimum dose delivery. * there are two main approaches to delivering laser energy, the pops-titration method and the fixed energy method that are the fixed-high and low-energy (the gaasterland's slow-coagulation technique). * of particular interest is which laser energy delivery method (slow-coagulation versus pops-titration) affords the optimal dose of photocoagulation necessary to achieve an effective long-term intraocular pressure (iop) reduction while minimizing the risk of adverse events related to overtreatment and retreatments especially in refractory glaucomatous eyes with dark iris color.

Eligibility criteria:
inclusion criteria: * refractory glaucoma (neovascular glaucoma) with * eyes with no visual potential and very high intraocular pressure (on maximal medical treatment) in which the intraocular pressure will probably cause corneal complications * eyes with no visual potential and very high intraocular pressure (on maximal medical treatment) in which the intraocular pressure cause eye pain and need pain relief * eyes with minimal useful vision and intraocular pressure over the target intraocular pressure * eyes in which trabeculectomy with mitomycin-c and/or drainage implants have a high probability of failure * eyes in which trabeculectomy with mitomycin-c and/or drainage implants have previously failed * patient refuses to undergo more aggressive intraocular surgery * patients whose general medical condition precludes invasive surgery exclusion criteria: * the visual acuity in the fellow eye is no light perception * have previously been treated by the transcleral cyclophotocoagulation * allergy to anesthetic medication * can not measure the intraocular pressure by the applanation method

Keywords: refractory glaucoma transcleral cyclophotocoagulation (tscpc) dark iris pops-titration slow-coagulation neovascular glaucoma
hartmann vs r/a in peritonitis by perforated diverticulitis

Conditions: Peritonitis Caused by Perforated Left-sided Colon Diverticulitis

Summary: this prospective randomized trial is to prove the equivalence of primary sigmoid resection with end colostomy(hartmann)(group a) and primary sigmoid resection and immediate anastomosis with diverting stoma (group b)with regard to morbidity and mortality in patients with peritonitis caused by perforated left-sided colon diverticulitis.


Eligibility criteria:
inclusion criteria: * intraoperative demonstrated peritonitis caused by perforated left-sided colon diverticulitis exclusion criteria:

Keywords: diverticulitis hartmann anastomosis
prospective analysis of intraoperative amniogen® injection in patients with rotator cuff tear

Conditions: Rotator Cuff Tears

Summary: purpose: the purpose of this article is to examine the clinical application of amniogen® in patients with rotator cuff tear. methods: the study was conducted on 100 adult participants with age over affected by unilateral shoulder rotator cuff tear and receiving rct repair. the investigators divided the participants in two groups, and the group a was treated with perioperative injection of amniogen® a, group b with perioperative normal saline. follow-up: every 1,3,and 12months, the investigators recheck physical exmianation at opd and recheck mri at postoperative 3 months.


Eligibility criteria:
inclusion criteria: * receiving unilateral shoulder rct repair in our hospital postoperative follow-up over 3 month exclusion criteria: * postoperative follow-up less than 3 month possible pregnency with coagulation disease nsaids intake during study period
nutritional deficiency after bariatric surgeries

Conditions: Nutritional Deficiency

Summary: comparing micro-nutrient deficiencies in postoperative morbid obese patients who will be undergoing gastric bypass and sleeve gastrectomy with regards to vit b 12, vitamin d,iron studies and calcium .

the general surgery department will be reviewed for a period of six months duration. all patients who admitted to the department and subjected to laparoscopic gp and sg during the study period will be included in the study after securing an informed consent; both written and verbal consent approved by the sohag ethics committee will be taken from all patients included in the study. patients will be followed for one year by laboratory testing of cbc, serum ferritin, and vitamin b 12, vitamin d and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative. the pre-operative and post-operative measures will be compared in patients who will be subjected to laparoscopic sleeve gastrectomy versus laparoscopic gastric bypass.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 65. 2. bmi more than 40 and more than 30 with co morbidities 3. both sexes with history of failed weight loss attempts in the past for two years and good motivation for surgery. exclusion criteria: 1. age less than 18, more than 65. 2. revisional bariatric surgery. 3. previous gastric surgery 4. patients with endocrinal disturbance except hypothyroidism and dm 5. psychological disturbed patients 6. females during pregnancy
randomized controlled trial of endoscopic dilation: triamcinolone injection

Conditions: Dysphagia

Summary: the purpose of this pilot study is to find out if adding triamcinolone (steroid) injection at the participant's initial esophagogastroduodenoscopy (egd) procedure will improve the opening of their esophagus and decrease the need for repeat dilations.

this is a randomized two-arms cross-over trial. in this study there are two groups, the control group and the triamcinolone treatment group. the cross-over design will apply only in the control group when patients are not responding to egd dilations alone (defined as no sustained improvement in baseline dysphagia) and they will be allowed to cross-over to the triamcinolone group and undergo 3 successive egds with triamcinolone injection. typically, triamcinolone (steroid) injection is given as a standard of care after several esophageal dilations are performed and failed to improve the condition. therefore, researchers want to find out if adding triamcinolone (steroid) injection at the participant's initial egd procedure will improve the opening of their esophagus and decrease the need for repeat dilations.

Eligibility criteria:
inclusion criteria: * patients who present for egd with dilation for dysphagia symptoms thought secondary to either radiation-induced stricture or anastomotic stricture based on history exclusion criteria: * inability to consent for the procedure * known coagulopathy \[international normalized ratio (inr) \>1.5, platelets \<75 k\] * endoscopic finding of a stricture that is not caused by either radiation or anastomotic narrowing * nasopharyngeal strictures

Keywords: radiation-induced stricture anastomotic stricture esophagogastroduodenoscopy (egd) dilation steroid injection triamcinolone difficulty swallowing
efficacy and safety study of z160 in subjects with postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: this study will compare z160 and placebo in patients with postherpetic neuralgia for safety and efficacy for a period of 6 weeks.


Eligibility criteria:
inclusion criteria: * provide written informed consent. * either sex but must be aged \>=18 years. * diagnosis of phn as defined by the presence of pain in the area affected by herpes zoster \>=6 months after the herpes zoster skin rash has healed. * pain score over the last week of \>=3 and \<=8 on the pi-nrs * if female, the subject must be postmenopausal , surgically sterilized for \>=3 months before the screening visit, or agree to use 2 reliable methods of contraception if of childbearing potential. if male, the subject must agree to use condoms. * willing and able to comply with all study procedures. exclusion criteria: * severe pain caused by diseases other than phn. * neurolytic or neurosurgical therapy for phn within 6 months of screening (subjects who received a spinal cord stimulator implant at least 6 months before screening are eligible, but the settings need to remain stable during the double blind study period without use of a magnet). * history of seizure, excluding pediatric febrile seizures, or currently has seizures. * stroke or transient ischemic attack (tia) \<=6 months before the screening visit. * history of or a current diagnosis of schizophrenia or bipolar disorder. * major depressive disorder or generalized anxiety disorder \<=6 months before the screening visit. subjects who are on stable doses of selective serotonin uptake inhibitors (ssris) for depression (other than major depressive disorder) are eligible for the study. * clinically significant alcohol or substance dependency \<=1 year before the screening visit * imminent risk of suicide (positive response to question 4 or 5 on the c-ssrs) or had a suicide attempt within 6 months before the screening visit. * clinically significant conditions that, in the investigator's opinion, may interfere with the study procedures or compromise the subject's safety. * malignancy (other than nonmetastatic basal or squamous cell carcinoma of the skin or carcinoma in situ of other organs that was surgically removed \>1 year before screening and has not recurred). * condition that is known to interfere with the absorption, distribution, metabolism, or excretion of drugs. * illness within 30 days before screening. * history of hypersensitivity to calcium channel blockers. * multiple drug allergies * opioids (at doses exceeding the equivalent of 15 mg of oral morphine) or a high-dose capsaicin patch (qutenza) \<=30 days before the screening visit. * moderate or strong cytochrome p450 inducer within 30 days before the screening visit. * digoxin or prohibited medications that cannot be discontinued before randomization. * other exclusions apply.